# PeptideScanner evidence objects: Difelikefalin

Every published version of the records placed with Difelikefalin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json. Selected public evidence only; not medical advice.

- Objects: 24
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03422653-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT03422653

> PeptideScanner retained ClinicalTrials.gov record NCT03422653 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct03422653-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03422653-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03422653-difelikefalin-v1
- Content SHA-256: `ff5cdab5ee7485f67d63c586b5ee5581980ca55157851be1cb881c67caf04f6f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03422653 ([`ctg-observation-nct03422653-2022-04-26-eb56076202fc`](#source-ctg-observation-nct03422653-2022-04-26-eb56076202fc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03422653 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03422653-2022-04-26-eb56076202fc`](#source-ctg-observation-nct03422653-2022-04-26-eb56076202fc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03422653 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03422653-2022-04-26-eb56076202fc`](#source-ctg-observation-nct03422653-2022-04-26-eb56076202fc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03422653-2022-04-26-eb56076202fc`](#source-ctg-observation-nct03422653-2022-04-26-eb56076202fc))

### Sources

<a id="source-ctg-observation-nct03422653-2022-04-26-eb56076202fc"></a>
- **ClinicalTrials.gov record NCT03422653 · retained source version 2022-04-26:eb56076202fcff452a6f606971f22df3ff30042793bc6801e8bdbbc0cd5154dd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03422653) (`ctg-observation-nct03422653-2022-04-26-eb56076202fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03422653." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03422653-difelikefalin-v1 SHA-256: ff5cdab5ee7485f67d63c586b5ee5581980ca55157851be1cb881c67caf04f6f.

---

<a id="clinicaltrials-gov-nct03617536-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT03617536

> PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct03617536-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-01-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03617536-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03617536-difelikefalin-v1
- Content SHA-256: `c176d1e9a2e547367aa20b1ab38b42e719dc94c014179cf88d654c901bbb3812`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03617536 ([`ctg-observation-nct03617536-2024-01-24-930ae76ffd71`](#source-ctg-observation-nct03617536-2024-01-24-930ae76ffd71))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03617536-2024-01-24-930ae76ffd71`](#source-ctg-observation-nct03617536-2024-01-24-930ae76ffd71))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03617536-2024-01-24-930ae76ffd71`](#source-ctg-observation-nct03617536-2024-01-24-930ae76ffd71))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03617536-2024-01-24-930ae76ffd71`](#source-ctg-observation-nct03617536-2024-01-24-930ae76ffd71))

### Sources

<a id="source-ctg-observation-nct03617536-2024-01-24-930ae76ffd71"></a>
- **ClinicalTrials.gov record NCT03617536 · retained source version 2024-01-24:930ae76ffd71d23d6abbe27377a5c2ee581a2f7abfc7d4468a0d941db8387f61** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03617536) (`ctg-observation-nct03617536-2024-01-24-930ae76ffd71`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03617536." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03617536-difelikefalin-v1 SHA-256: c176d1e9a2e547367aa20b1ab38b42e719dc94c014179cf88d654c901bbb3812.

---

<a id="clinicaltrials-gov-nct03636269-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT03636269

> PeptideScanner retained ClinicalTrials.gov record NCT03636269 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct03636269-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03636269-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03636269-difelikefalin-v1
- Content SHA-256: `fd5d68214d1d4100540abed0eeb289f18aceb1d7c70c27c907da17607bc404c0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03636269 ([`ctg-observation-nct03636269-2022-04-26-07a43f15e7b3`](#source-ctg-observation-nct03636269-2022-04-26-07a43f15e7b3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03636269 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03636269-2022-04-26-07a43f15e7b3`](#source-ctg-observation-nct03636269-2022-04-26-07a43f15e7b3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03636269 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-04-26, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03636269-2022-04-26-07a43f15e7b3`](#source-ctg-observation-nct03636269-2022-04-26-07a43f15e7b3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03636269-2022-04-26-07a43f15e7b3`](#source-ctg-observation-nct03636269-2022-04-26-07a43f15e7b3))

### Sources

<a id="source-ctg-observation-nct03636269-2022-04-26-07a43f15e7b3"></a>
- **ClinicalTrials.gov record NCT03636269 · retained source version 2022-04-26:07a43f15e7b3c8a57e207546a164fbc33bc2500883ff3ad61c0f67701cad92b7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03636269) (`ctg-observation-nct03636269-2022-04-26-07a43f15e7b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03636269." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03636269-difelikefalin-v1 SHA-256: fd5d68214d1d4100540abed0eeb289f18aceb1d7c70c27c907da17607bc404c0.

---

<a id="clinicaltrials-gov-nct03998163-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT03998163

> PeptideScanner retained ClinicalTrials.gov record NCT03998163 at 2026-11-15T21:56:33.343Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct03998163-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03998163-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03998163-difelikefalin-v1
- Content SHA-256: `a55075181fb90f65adedee4b5cb9d3437bf3e68bb133e962168d8553ed347c5d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03998163 ([`ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7`](#source-ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03998163 at 2026-11-15T21:56:33.343Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7`](#source-ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03998163 at 2026-11-15T21:56:33.343Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7`](#source-ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7`](#source-ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7))

### Sources

<a id="source-ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7"></a>
- **ClinicalTrials.gov record NCT03998163 · retained source version 2021-10-15:49a3d7f56ec770018a558f8eba3c19dd2b307ce23764b3770dad3f28284a7d2f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03998163) (`ctg-observation-nct03998163-2021-10-15-49a3d7f56ec7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03998163." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct03998163-difelikefalin-v1 SHA-256: a55075181fb90f65adedee4b5cb9d3437bf3e68bb133e962168d8553ed347c5d.

---

<a id="clinicaltrials-gov-nct05533008-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT05533008

> PeptideScanner retained ClinicalTrials.gov record NCT05533008 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-09-08, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct05533008-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05533008-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct05533008-difelikefalin-v1
- Content SHA-256: `7494dd7287c98735586f55ad4e183e1bb8c75109c4ef34a893b5177397b5135a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05533008 ([`ctg-observation-nct05533008-2022-09-08-b6fca5c5f316`](#source-ctg-observation-nct05533008-2022-09-08-b6fca5c5f316))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05533008 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-09-08, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct05533008-2022-09-08-b6fca5c5f316`](#source-ctg-observation-nct05533008-2022-09-08-b6fca5c5f316))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05533008 at 2026-11-15T21:56:33.343Z. Its registry update date was 2022-09-08, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct05533008-2022-09-08-b6fca5c5f316`](#source-ctg-observation-nct05533008-2022-09-08-b6fca5c5f316))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05533008-2022-09-08-b6fca5c5f316`](#source-ctg-observation-nct05533008-2022-09-08-b6fca5c5f316))

### Sources

<a id="source-ctg-observation-nct05533008-2022-09-08-b6fca5c5f316"></a>
- **ClinicalTrials.gov record NCT05533008 · retained source version 2022-09-08:b6fca5c5f3168b56d6ea7c5a4e872f41a9fa11ffa7e06d4fd254559067514544** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05533008) (`ctg-observation-nct05533008-2022-09-08-b6fca5c5f316`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05533008." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct05533008-difelikefalin-v1 SHA-256: 7494dd7287c98735586f55ad4e183e1bb8c75109c4ef34a893b5177397b5135a.

---

<a id="clinicaltrials-gov-nct06593392-difelikefalin-v1"></a>

## ClinicalTrials.gov record NCT06593392

> PeptideScanner retained ClinicalTrials.gov record NCT06593392 at 2026-11-15T21:56:33.343Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was difelikefalin.

- Evidence object: `story:clinicaltrials-gov-nct06593392-difelikefalin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06593392-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct06593392-difelikefalin-v1
- Content SHA-256: `939dfffff106fa112ba4c17634e759f54b1fa37fe7fe3c3d937df0e53531029f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06593392 ([`ctg-observation-nct06593392-2026-10-23-0d3887bcc953`](#source-ctg-observation-nct06593392-2026-10-23-0d3887bcc953))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06593392 at 2026-11-15T21:56:33.343Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct06593392-2026-10-23-0d3887bcc953`](#source-ctg-observation-nct06593392-2026-10-23-0d3887bcc953))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06593392 at 2026-11-15T21:56:33.343Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was difelikefalin. ([`ctg-observation-nct06593392-2026-10-23-0d3887bcc953`](#source-ctg-observation-nct06593392-2026-10-23-0d3887bcc953))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06593392-2026-10-23-0d3887bcc953`](#source-ctg-observation-nct06593392-2026-10-23-0d3887bcc953))

### Sources

<a id="source-ctg-observation-nct06593392-2026-10-23-0d3887bcc953"></a>
- **ClinicalTrials.gov record NCT06593392 · retained source version 2026-10-23:0d3887bcc9534de7ee27be4f7a9a47d7f30e16bd550597cf8633b2b2a14d4241** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06593392) (`ctg-observation-nct06593392-2026-10-23-0d3887bcc953`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06593392." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#clinicaltrials-gov-nct06593392-difelikefalin-v1 SHA-256: 939dfffff106fa112ba4c17634e759f54b1fa37fe7fe3c3d937df0e53531029f.

---

<a id="fda-drugs-anda220919-v1"></a>

## Drugs@FDA application ANDA220919

> The official Drugs@FDA dataset lists original submission 1 for ANDA 220919 with status AP dated 2026-08-31, and names difelikefalin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda220919:v1`
- Evidence domain: Regulatory
- Date in source: 2026-08-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda220919/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#fda-drugs-anda220919-v1
- Content SHA-256: `74f2e997b27a8537f91957b018994bd4978b1c077cb964260efc064ee98b8832`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA220919 ([`fda-drugs-anda220919-2026-08-31-dfdf86f15e3b`](#source-fda-drugs-anda220919-2026-08-31-dfdf86f15e3b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 220919 with status AP dated 2026-08-31, and names difelikefalin acetate among the application record's active ingredients. ([`fda-drugs-anda220919-2026-08-31-dfdf86f15e3b`](#source-fda-drugs-anda220919-2026-08-31-dfdf86f15e3b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 220919 with status AP dated 2026-08-31, and names difelikefalin acetate among the application record's active ingredients. ([`fda-drugs-anda220919-2026-08-31-dfdf86f15e3b`](#source-fda-drugs-anda220919-2026-08-31-dfdf86f15e3b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda220919-2026-08-31-dfdf86f15e3b`](#source-fda-drugs-anda220919-2026-08-31-dfdf86f15e3b))

### Sources

<a id="source-fda-drugs-anda220919-2026-08-31-dfdf86f15e3b"></a>
- **Drugs@FDA application ANDA220919 · original submission status AP · 2026-08-31 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA220919%22&limit=1) (`fda-drugs-anda220919-2026-08-31-dfdf86f15e3b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA220919." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#fda-drugs-anda220919-v1 SHA-256: 74f2e997b27a8537f91957b018994bd4978b1c077cb964260efc064ee98b8832.

---

<a id="fda-drugs-nda214916-v1"></a>

## Drugs@FDA application NDA214916

> The official Drugs@FDA dataset lists original submission 1 for NDA 214916 with status AP dated 2021-08-23, and names difelikefalin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda214916:v1`
- Evidence domain: Regulatory
- Date in source: 2021-08-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda214916/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#fda-drugs-nda214916-v1
- Content SHA-256: `3769300a7be031954409b64feb2e9272cc1149151d58630ea4b22ba8df9f124a`

### Claims and source pins

#### Headline

Drugs@FDA application NDA214916 ([`fda-drugs-nda214916-2021-08-23-e541f47084d2`](#source-fda-drugs-nda214916-2021-08-23-e541f47084d2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 214916 with status AP dated 2021-08-23, and names difelikefalin acetate among the application record's active ingredients. ([`fda-drugs-nda214916-2021-08-23-e541f47084d2`](#source-fda-drugs-nda214916-2021-08-23-e541f47084d2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 214916 with status AP dated 2021-08-23, and names difelikefalin acetate among the application record's active ingredients. ([`fda-drugs-nda214916-2021-08-23-e541f47084d2`](#source-fda-drugs-nda214916-2021-08-23-e541f47084d2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda214916-2021-08-23-e541f47084d2`](#source-fda-drugs-nda214916-2021-08-23-e541f47084d2))

### Sources

<a id="source-fda-drugs-nda214916-2021-08-23-e541f47084d2"></a>
- **Drugs@FDA application NDA214916 · original submission status AP · 2021-08-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA214916%22&limit=1) (`fda-drugs-nda214916-2021-08-23-e541f47084d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA214916." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#fda-drugs-nda214916-v1 SHA-256: 3769300a7be031954409b64feb2e9272cc1149151d58630ea4b22ba8df9f124a.

---

<a id="federal-register-2023-10710-v1"></a>

## Federal Register notice 2023-10710

> The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

- Evidence object: `story:federal-register-2023-10710:v1`
- Evidence domain: Regulatory
- Date in source: 2023-05-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-10710/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#federal-register-2023-10710-v1
- Content SHA-256: `5ec41cc90b5246fadcb137129a2c753e01dd9da3e14743784076db779bc95b6f`

### Claims and source pins

#### Headline

Federal Register notice 2023-10710 ([`federal-register-2023-10710-498cd37df308`](#source-federal-register-2023-10710-498cd37df308))

#### Summary

The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin. ([`federal-register-2023-10710-498cd37df308`](#source-federal-register-2023-10710-498cd37df308))

#### Paragraph 1

The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin. ([`federal-register-2023-10710-498cd37df308`](#source-federal-register-2023-10710-498cd37df308))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-10710-498cd37df308`](#source-federal-register-2023-10710-498cd37df308))

### Sources

<a id="source-federal-register-2023-10710-498cd37df308"></a>
- **Federal Register notice 2023-10710 · published 2023-05-19 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-05-19/pdf/2023-10710.pdf) (`federal-register-2023-10710-498cd37df308`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-10710." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#federal-register-2023-10710-v1 SHA-256: 5ec41cc90b5246fadcb137129a2c753e01dd9da3e14743784076db779bc95b6f.

---

<a id="federal-register-2023-26106-v1"></a>

## Federal Register notice 2023-26106

> The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

- Evidence object: `story:federal-register-2023-26106:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-26106/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#federal-register-2023-26106-v1
- Content SHA-256: `47bda51e103f0451a540844df7d31601e7c7154afb323f9a5c6a3c1fe51652f0`

### Claims and source pins

#### Headline

Federal Register notice 2023-26106 ([`federal-register-2023-26106-a0d88cd9b847`](#source-federal-register-2023-26106-a0d88cd9b847))

#### Summary

The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin. ([`federal-register-2023-26106-a0d88cd9b847`](#source-federal-register-2023-26106-a0d88cd9b847))

#### Paragraph 1

The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin. ([`federal-register-2023-26106-a0d88cd9b847`](#source-federal-register-2023-26106-a0d88cd9b847))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-26106-a0d88cd9b847`](#source-federal-register-2023-26106-a0d88cd9b847))

### Sources

<a id="source-federal-register-2023-26106-a0d88cd9b847"></a>
- **Federal Register notice 2023-26106 · published 2023-11-28 · Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26106.pdf) (`federal-register-2023-26106-a0d88cd9b847`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-26106." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#federal-register-2023-26106-v1 SHA-256: 47bda51e103f0451a540844df7d31601e7c7154afb323f9a5c6a3c1fe51652f0.

---

<a id="pubmed-pmid-31702883-difelikefalin-v1"></a>

## A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.

> PubMed lists PMID 31702883 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2019-11-08 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31702883-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31702883-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-31702883-difelikefalin-v1
- Content SHA-256: `2857906c1fe00fe860acf4dbf240d87cd8df4c8f738473350b0178206a8bb1be`

### Claims and source pins

#### Headline

A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. ([`pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6`](#source-pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6))

#### Summary

PubMed lists PMID 31702883 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2019-11-08 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6`](#source-pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6))

#### Paragraph 1

PubMed lists PMID 31702883 in The New England journal of medicine as Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2019-11-08 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6`](#source-pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6`](#source-pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6))

### Sources

<a id="source-pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6"></a>
- **A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2026-05-18:current:41b285eaf9e6f9c324df31b5d27169b0109ce5f09daad2a6f90bf99d86c9bf47** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31702883/) (`pubmed-observation-pmid-31702883-2026-05-18-41b285eaf9e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-31702883-difelikefalin-v1 SHA-256: 2857906c1fe00fe860acf4dbf240d87cd8df4c8f738473350b0178206a8bb1be.

---

<a id="pubmed-pmid-31940704-difelikefalin-v1"></a>

## Difelikefalin for the Treatment of Uremic Pruritus.

> PubMed lists PMID 31940704 in The New England journal of medicine as Editorial, Comment, with publication-date metadata of 2020-01-16 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31940704-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31940704-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-31940704-difelikefalin-v1
- Content SHA-256: `0fa1b96e52d71e4c72e93565cbc49dabcc9493044e808a84d88f84f2e378825f`

### Claims and source pins

#### Headline

Difelikefalin for the Treatment of Uremic Pruritus. ([`pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed`](#source-pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed))

#### Summary

PubMed lists PMID 31940704 in The New England journal of medicine as Editorial, Comment, with publication-date metadata of 2020-01-16 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed`](#source-pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed))

#### Paragraph 1

PubMed lists PMID 31940704 in The New England journal of medicine as Editorial, Comment, with publication-date metadata of 2020-01-16 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed`](#source-pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed`](#source-pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed))

### Sources

<a id="source-pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed"></a>
- **Difelikefalin for the Treatment of Uremic Pruritus. · retained source version 1:2020-01-27:current:96e1bee0ceed1848bd7b25252a133bc05df6b6c8c3a0a8b28873dcc821a49eae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31940704/) (`pubmed-observation-pmid-31940704-2020-01-27-96e1bee0ceed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin for the Treatment of Uremic Pruritus." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-31940704-difelikefalin-v1 SHA-256: 0fa1b96e52d71e4c72e93565cbc49dabcc9493044e808a84d88f84f2e378825f.

---

<a id="pubmed-pmid-32433845-difelikefalin-v1"></a>

## Difelikefalin in Hemodialysis Patients with Pruritus.

> PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32433845-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32433845-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433845-difelikefalin-v1
- Content SHA-256: `12f28a9215dd85b063789173517f03f4bc6443ce4ec1a39c8e40af1d3c113a6a`

### Claims and source pins

#### Headline

Difelikefalin in Hemodialysis Patients with Pruritus. ([`pubmed-observation-pmid-32433845-2023-09-29-595b0123b864`](#source-pubmed-observation-pmid-32433845-2023-09-29-595b0123b864))

#### Summary

PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433845-2023-09-29-595b0123b864`](#source-pubmed-observation-pmid-32433845-2023-09-29-595b0123b864))

#### Paragraph 1

PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433845-2023-09-29-595b0123b864`](#source-pubmed-observation-pmid-32433845-2023-09-29-595b0123b864))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32433845-2023-09-29-595b0123b864`](#source-pubmed-observation-pmid-32433845-2023-09-29-595b0123b864))

### Sources

<a id="source-pubmed-observation-pmid-32433845-2023-09-29-595b0123b864"></a>
- **Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:595b0123b8641c0a998479218845a319bb003ef36555e8a2476ad6f8dc164f84** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32433845/) (`pubmed-observation-pmid-32433845-2023-09-29-595b0123b864`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in Hemodialysis Patients with Pruritus." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433845-difelikefalin-v1 SHA-256: 12f28a9215dd85b063789173517f03f4bc6443ce4ec1a39c8e40af1d3c113a6a.

---

<a id="pubmed-pmid-32433846-difelikefalin-v1"></a>

## Difelikefalin in Hemodialysis Patients with Pruritus.

> PubMed lists PMID 32433846 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32433846-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32433846-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433846-difelikefalin-v1
- Content SHA-256: `289b88873397af80ca80910dd482c7b201d34a27d53155ad4600f1e197621d58`

### Claims and source pins

#### Headline

Difelikefalin in Hemodialysis Patients with Pruritus. ([`pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016`](#source-pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016))

#### Summary

PubMed lists PMID 32433846 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016`](#source-pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016))

#### Paragraph 1

PubMed lists PMID 32433846 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016`](#source-pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016`](#source-pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016))

### Sources

<a id="source-pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016"></a>
- **Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:f8f03417a01638983e66ff337ca6d0e664623c4bacc4a8387f8e6371c1d61272** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32433846/) (`pubmed-observation-pmid-32433846-2023-09-29-f8f03417a016`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in Hemodialysis Patients with Pruritus." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433846-difelikefalin-v1 SHA-256: 289b88873397af80ca80910dd482c7b201d34a27d53155ad4600f1e197621d58.

---

<a id="pubmed-pmid-32433847-difelikefalin-v1"></a>

## Difelikefalin in Hemodialysis Patients with Pruritus.

> PubMed lists PMID 32433847 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32433847-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32433847-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433847-difelikefalin-v1
- Content SHA-256: `b7fbf508d68a50fe348daafb5491e70bdc35712c96236c7db80d37c6823c1a48`

### Claims and source pins

#### Headline

Difelikefalin in Hemodialysis Patients with Pruritus. ([`pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14`](#source-pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14))

#### Summary

PubMed lists PMID 32433847 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14`](#source-pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14))

#### Paragraph 1

PubMed lists PMID 32433847 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14`](#source-pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14`](#source-pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14))

### Sources

<a id="source-pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14"></a>
- **Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:517f7cd38f14bb0e05b4f4ed4b7b002180cb50cb468c095a29e6243478056790** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32433847/) (`pubmed-observation-pmid-32433847-2023-09-29-517f7cd38f14`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in Hemodialysis Patients with Pruritus." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433847-difelikefalin-v1 SHA-256: b7fbf508d68a50fe348daafb5491e70bdc35712c96236c7db80d37c6823c1a48.

---

<a id="pubmed-pmid-32433848-difelikefalin-v1"></a>

## Difelikefalin in Hemodialysis Patients with Pruritus. Reply.

> PubMed lists PMID 32433848 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32433848-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32433848-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433848-difelikefalin-v1
- Content SHA-256: `a3b4d9a908280e7911dc91bf01f4e62f0f126b4f3c22702597d132f5d5167bfd`

### Claims and source pins

#### Headline

Difelikefalin in Hemodialysis Patients with Pruritus. Reply. ([`pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5`](#source-pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5))

#### Summary

PubMed lists PMID 32433848 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5`](#source-pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5))

#### Paragraph 1

PubMed lists PMID 32433848 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5`](#source-pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5`](#source-pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5))

### Sources

<a id="source-pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5"></a>
- **Difelikefalin in Hemodialysis Patients with Pruritus. Reply. · retained source version 1:2020-05-25:current:8f92abb1fed57e180c9f25b26c1ea763903f1c293e2323c5d8ea4c43db46082b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32433848/) (`pubmed-observation-pmid-32433848-2020-05-25-8f92abb1fed5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in Hemodialysis Patients with Pruritus. Reply." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-32433848-difelikefalin-v1 SHA-256: a3b4d9a908280e7911dc91bf01f4e62f0f126b4f3c22702597d132f5d5167bfd.

---

<a id="pubmed-pmid-33190563-difelikefalin-v1"></a>

## An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.

> PubMed lists PMID 33190563 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33190563-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-04-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33190563-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-33190563-difelikefalin-v1
- Content SHA-256: `8e8c66776881e5f1ca00c4a9a3697f119b3acccf39eda56f71fa25d30f3f5121`

### Claims and source pins

#### Headline

An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. ([`pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd`](#source-pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd))

#### Summary

PubMed lists PMID 33190563 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd`](#source-pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd))

#### Paragraph 1

PubMed lists PMID 33190563 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd`](#source-pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd`](#source-pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd))

### Sources

<a id="source-pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd"></a>
- **An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. · retained source version 1:2021-04-27:current:7cc036b8f0cdd888f1146ae4c86b7b856c11de08b4de30444067fbc12ec6e1e7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33190563/) (`pubmed-observation-pmid-33190563-2021-04-27-7cc036b8f0cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-33190563-difelikefalin-v1 SHA-256: 8e8c66776881e5f1ca00c4a9a3697f119b3acccf39eda56f71fa25d30f3f5121.

---

<a id="pubmed-pmid-34849553-difelikefalin-v1"></a>

## Difelikefalin Acetate.

> PubMed lists PMID 34849553 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2022-01-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34849553-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34849553-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-34849553-difelikefalin-v1
- Content SHA-256: `5142ee80fe8ee8437e4793a8bbdfbfd3338762daab98c7cee3ac50057faa668b`

### Claims and source pins

#### Headline

Difelikefalin Acetate. ([`pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9`](#source-pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9))

#### Summary

PubMed lists PMID 34849553 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2022-01-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9`](#source-pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9))

#### Paragraph 1

PubMed lists PMID 34849553 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2022-01-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9`](#source-pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9`](#source-pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9))

### Sources

<a id="source-pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9"></a>
- **Difelikefalin Acetate. · retained source version 1:2021-12-21:current:5de422e8a3b9be711a749b06ea3b0dc1bf16a76955949b8afeda48e289412a53** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34849553/) (`pubmed-observation-pmid-34849553-2021-12-21-5de422e8a3b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin Acetate." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-34849553-difelikefalin-v1 SHA-256: 5142ee80fe8ee8437e4793a8bbdfbfd3338762daab98c7cee3ac50057faa668b.

---

<a id="pubmed-pmid-35337427-difelikefalin-v1"></a>

## New Drugs Update: Finerenone, Difelikefalin, and Avacopan.

> PubMed lists PMID 35337427 in The Senior care pharmacist as Journal Article, with publication-date metadata of 2022-04-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35337427-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35337427-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-35337427-difelikefalin-v1
- Content SHA-256: `f04d4ec41b5d2e6029e7bc0fcdb686f6a8abdfca2dd8931e0a5e59400e979a24`

### Claims and source pins

#### Headline

New Drugs Update: Finerenone, Difelikefalin, and Avacopan. ([`pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c`](#source-pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c))

#### Summary

PubMed lists PMID 35337427 in The Senior care pharmacist as Journal Article, with publication-date metadata of 2022-04-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c`](#source-pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c))

#### Paragraph 1

PubMed lists PMID 35337427 in The Senior care pharmacist as Journal Article, with publication-date metadata of 2022-04-01 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c`](#source-pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c`](#source-pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c))

### Sources

<a id="source-pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c"></a>
- **New Drugs Update: Finerenone, Difelikefalin, and Avacopan. · retained source version 1:2026-11-09:current:19137ebabf3c5a83d3e4540f522ef6c5bcfd6b24f14c95e4540b073548dd1914** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35337427/) (`pubmed-observation-pmid-35337427-2026-11-09-19137ebabf3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "New Drugs Update: Finerenone, Difelikefalin, and Avacopan." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-35337427-difelikefalin-v1 SHA-256: f04d4ec41b5d2e6029e7bc0fcdb686f6a8abdfca2dd8931e0a5e59400e979a24.

---

<a id="pubmed-pmid-36780675-difelikefalin-v1"></a>

## Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.

> PubMed lists PMID 36780675 in The New England journal of medicine as Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-09 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36780675-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36780675-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-36780675-difelikefalin-v1
- Content SHA-256: `c4cfdb38c2dabfc4f347712548b390ffafac76327258bdfa8dbbf9d645bd1e46`

### Claims and source pins

#### Headline

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica. ([`pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3`](#source-pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3))

#### Summary

PubMed lists PMID 36780675 in The New England journal of medicine as Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-09 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3`](#source-pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3))

#### Paragraph 1

PubMed lists PMID 36780675 in The New England journal of medicine as Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-09 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3`](#source-pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3`](#source-pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3))

### Sources

<a id="source-pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3"></a>
- **Phase 2 Trial of Difelikefalin in Notalgia Paresthetica. · retained source version 1:2026-05-18:current:482b9f86abf3e8c9746c5d765626f6d98876225f759f98d4db575b32ccfd07b0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36780675/) (`pubmed-observation-pmid-36780675-2026-05-18-482b9f86abf3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase 2 Trial of Difelikefalin in Notalgia Paresthetica." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-36780675-difelikefalin-v1 SHA-256: c4cfdb38c2dabfc4f347712548b390ffafac76327258bdfa8dbbf9d645bd1e46.

---

<a id="pubmed-pmid-38253036-difelikefalin-v1"></a>

## Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.

> PubMed lists PMID 38253036 in American journal of nephrology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38253036-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38253036-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-38253036-difelikefalin-v1
- Content SHA-256: `56e827f2d72dfba9f8ee3397f04b0da2ac37e33c83bb2c2d64ecf5e87c961046`

### Claims and source pins

#### Headline

Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2. ([`pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d`](#source-pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d))

#### Summary

PubMed lists PMID 38253036 in American journal of nephrology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d`](#source-pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d))

#### Paragraph 1

PubMed lists PMID 38253036 in American journal of nephrology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d`](#source-pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d`](#source-pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d))

### Sources

<a id="source-pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d"></a>
- **Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2. · retained source version 1:2026-05-26:current:df4dd457417db0dc693aa6cc1d27cfd4e933b8119e3a5184c13a49ba48429e2e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38253036/) (`pubmed-observation-pmid-38253036-2026-05-26-df4dd457417d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-38253036-difelikefalin-v1 SHA-256: 56e827f2d72dfba9f8ee3397f04b0da2ac37e33c83bb2c2d64ecf5e87c961046.

---

<a id="pubmed-pmid-38320524-difelikefalin-v1"></a>

## Difelikefalin for Hemodialysis Patients with Pruritus in Japan.

> PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38320524-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38320524-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-38320524-difelikefalin-v1
- Content SHA-256: `8be75472830af6386c0697e5ecf3926f7ffcd43f4e463a4e0df84b4c97f5bab7`

### Claims and source pins

#### Headline

Difelikefalin for Hemodialysis Patients with Pruritus in Japan. ([`pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976`](#source-pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976))

#### Summary

PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976`](#source-pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976))

#### Paragraph 1

PubMed lists PMID 38320524 in NEJM evidence as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976`](#source-pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976`](#source-pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976))

### Sources

<a id="source-pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976"></a>
- **Difelikefalin for Hemodialysis Patients with Pruritus in Japan. · retained source version 1:2025-12-05:current:e7133fc4a976247b1c0c97bf6f998d2585fa2a7af95cb10ff7fff85ac79ced22** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38320524/) (`pubmed-observation-pmid-38320524-2025-12-05-e7133fc4a976`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin for Hemodialysis Patients with Pruritus in Japan." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-38320524-difelikefalin-v1 SHA-256: 8be75472830af6386c0697e5ecf3926f7ffcd43f4e463a4e0df84b4c97f5bab7.

---

<a id="pubmed-pmid-39037824-difelikefalin-v1"></a>

## Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies.

> PubMed lists PMID 39037824 in Kidney360 as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39037824-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39037824-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-39037824-difelikefalin-v1
- Content SHA-256: `57485b9bfc98e0af54501cde4d724d905bdabc8fd62d4ef9470ea98837fb699f`

### Claims and source pins

#### Headline

Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies. ([`pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df`](#source-pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df))

#### Summary

PubMed lists PMID 39037824 in Kidney360 as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df`](#source-pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df))

#### Paragraph 1

PubMed lists PMID 39037824 in Kidney360 as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df`](#source-pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df`](#source-pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df))

### Sources

<a id="source-pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df"></a>
- **Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies. · retained source version 1:2026-03-12:current:8474132dd9df1d64999070712e0cfe872875729c9a82d840bbd9bc53478a9071** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39037824/) (`pubmed-observation-pmid-39037824-2026-03-12-8474132dd9df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-39037824-difelikefalin-v1 SHA-256: 57485b9bfc98e0af54501cde4d724d905bdabc8fd62d4ef9470ea98837fb699f.

---

<a id="pubmed-pmid-39712488-difelikefalin-v1"></a>

## Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis.

> PubMed lists PMID 39712488 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-12-06 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39712488-difelikefalin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39712488-difelikefalin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-39712488-difelikefalin-v1
- Content SHA-256: `4c08efee2b0755cbf9ec3f42f90edcbaa186b2ce24d3da4868c1569d60092d61`

### Claims and source pins

#### Headline

Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis. ([`pubmed-observation-pmid-39712488-2025-01-04-455e9c852376`](#source-pubmed-observation-pmid-39712488-2025-01-04-455e9c852376))

#### Summary

PubMed lists PMID 39712488 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-12-06 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39712488-2025-01-04-455e9c852376`](#source-pubmed-observation-pmid-39712488-2025-01-04-455e9c852376))

#### Paragraph 1

PubMed lists PMID 39712488 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-12-06 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39712488-2025-01-04-455e9c852376`](#source-pubmed-observation-pmid-39712488-2025-01-04-455e9c852376))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39712488-2025-01-04-455e9c852376`](#source-pubmed-observation-pmid-39712488-2025-01-04-455e9c852376))

### Sources

<a id="source-pubmed-observation-pmid-39712488-2025-01-04-455e9c852376"></a>
- **Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis. · retained source version 1:2025-01-04:current:455e9c852376153aca1b2e7b21efa24e4a2df0798d9a727c6104812d7588689c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39712488/) (`pubmed-observation-pmid-39712488-2025-01-04-455e9c852376`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/difelikefalin.json#pubmed-pmid-39712488-difelikefalin-v1 SHA-256: 4c08efee2b0755cbf9ec3f42f90edcbaa186b2ce24d3da4868c1569d60092d61.

